Acquirer Synergies Following the acquisition by Unchained Labs, pursue cross-sell and integration opportunities by offering NanoView’s exosome analysis capabilities to the acquirer's customer base, with bundled instruments, services and consumables to grow share of wallet.

EV Biomarker Demand Position ExoView as a high-throughput, cost-effective solution for extracellular vesicle and exosome biomarker studies in oncology and immune-oncology to support research, diagnostics and therapeutic monitoring.

Local Collaboration Leverage the Boston location and past collaborations with major medical centers to pursue partnerships with academic hospitals and biotech incubators for sponsored research, joint development and pilot programs.

SMB Growth Fit Target lean, midsize biotech and academic labs with high-value bundles that combine hardware, software, training and service, aligning with procurement cycles and budget constraints typical of smaller companies.

Product Upsell Capitalize on a new generation ExoView offering by promoting platform upgrades, enhanced analytics and consumables, plus service agreements and trade-in programs to convert existing users to advanced capabilities.